Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Distribution
P/S (TTM)
0.6
EV / FCF (TTM)
1950
Covetrus, Inc. functions as a technology and services provider for the animal health sector. The company supplies a comprehensive range of animal health consumables, including its own branded and proprietary items, along with diverse equipment (small and large), laboratory supplies, and associated repair services. It further offers a full spectrum of pharmaceuticals—encompassing branded, generic, and vaccine products, surgical instruments, diagnostic kits, infection control solutions, parasiticides, and nutritional supplements—to both wholesale and retail clients. Beyond physical goods, Covetrus delivers critical value-added services such as inventory management, e-commerce platforms, and professional development programs for veterinary practitioners. Its technology portfolio includes practice management software, data analytics applications, and client communication tools aimed at boosting operational efficiency and enhancing business health. These integrated offerings extend to client reminders, data backup, hardware sales and support, and credit card processing capabilities for veterinary practices and clinics. Additionally, the company manages the distribution of finished pharmaceutical products and offers specialty compounding services, complemented by logistics, manufacturer incentives, and data integration support. Covetrus supports veterinary practices and animal health clinics across the companion animal, equine, and livestock sectors, primarily within North America, Europe, and the Asia Pacific. Established in 2018 under the name HS Spinco, Inc. and headquartered in Portland, Maine, Covetrus, Inc. transitioned to private ownership on October 13, 2022.
www.covetrus.comNo one on the platform currently holds CVET.
No tracked institution reports a position in CVET as of their last filing.
No one on the platform has traded CVET yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Analyst estimates unavailable for this ticker.
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2022-08-04 | $0.25 | $0.25 | +0.0% |
| 2022-05-05 | $0.22 | $0.25 | +13.6% |
| 2022-02-24 | $0.25 | $0.26 | +4.0% |
| 2021-11-04 | $0.23 | $0.23 | +0.0% |
| 2021-08-05 | $0.24 | $0.26 | +8.3% |
| 2021-05-06 | $0.17 | $0.21 | +23.5% |
| 2021-03-01 | $0.16 | $0.21 | +31.2% |
| 2020-11-10 | $0.18 | $0.26 | +44.4% |
| $2.9B |
| — |
| MORFMorphic Holding, Inc. | $56.99 | +0.04% | $2.9B | — |
| MYOVMyovant Sciences Ltd. | $26.98 | -0.04% | $2.6B | — |
Source: Financial Modeling Prep · peers by sector/industry
$CVET Covetrus, Inc. (NASDAQ:CVET): Navigating the Animal Health Landscape with Precision https://beyondspx.com/article/covetrus-inc-nasdaq-cvet-navigating-the-animal-health-landscape-with-precision
View on StockTwits ↗$CVET Covetrus, Inc. (NASDAQ:CVET): Navigating the Animal Health Landscape with Precision http://beyondspx.com/2024/08/04/covetrus-inc-nasdaqcvet-navigating-the-animal-health-landscape-with-precision/
View on StockTwits ↗$CVET company-wide layoff today due to structural and strategic direction changes. Earlier this year, $CVET pleaded guilty to causing the introduction and delivery of veterinary prescription drugs that were misbranded into interstate commerce and has been sentenced to 1-year probation by a federal court in Abingdon, Virginia. As part of the agreement, Covetrus, based in Portland, Maine—must also pay more than $23M in criminal forfeitures and fines. https://www.mainebiz.biz/article/covetrus-lays-off-some-employees-in-restructuring
View on StockTwits ↗$CVET - Option Volatility signal: Covetrus pin risk is decreasing https://www.macroaxis.com/stock-options/CVET/Covetrus?utm_source=dlvr.it&utm_medium=stocktwits
View on StockTwits ↗$CVET Covetrus Names Ajoy Karna as Chief Financial Officer https://www.stocktitan.net/news/CVET/covetrus-names-ajoy-karna-as-chief-financial-qhzd48klc8uj.html
View on StockTwits ↗$CVET New Press Release: Covetrus Names Ajoy Karna as Chief Financial Officer Covetrus®, a global leader in animal-health technology and services, today announced the appointment of Ajoy Karna as executive vice president and chief financial officer. Karna succeeds Matthew Foulston, who announced previously his retirement from the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221208005120/en/ Ajoy Karna, CFO, Covetrus (Photo: Business Wire) “Ajoy is a strategic and operational leader with deep global expertise in finance and driving companywide business growth,” said Benjamin Wolin, president and CEO of Covetrus. “He is a welcome addition to our leadership team, and Covetrus and our stakeholders wi (...) https://webchronicletoday.com?p=314920
View on StockTwits ↗$ELAN big news in animal health, stock ticker ALRTF ($0.07) just partnered with $CVET to sell the GluCurve Pet CGM, the first and only Continuous Glucose Monitor for diabetic pets. Great buying opportunity to get in on the ground floor of ALRT before they uplist to the NYSE American in Q1 https://finance.yahoo.com/news/alr-technologies-announces-co-branded-133300364.html
View on StockTwits ↗$ABC stock ticker ALRTF ($0.07) just partnered with $CVET to sell the GluCurve Pet CGM, the first and only Continuous Glucose Monitor for diabetic pets. This is going to help Covetrus take even more business from MWI which is going to hurt ABC. Great buying opportunity to get in on the ground floor of ALRT before they uplist to the NYSE American in Q1 https://finance.yahoo.com/news/alr-technologies-announces-co-branded-133300364.html
View on StockTwits ↗$PDCO stock ticker ALRTF ($0.07) just partnered with $CVET to sell the GluCurve Pet CGM, the first and only Continuous Glucose Monitor for diabetic pets. This is going to help Covetrus take even more business from Patterson. Great buying opportunity to get in on the ground floor of ALRT before they uplist to the NYSE American in Q1 https://finance.yahoo.com/news/alr-technologies-announces-co-branded-133300364.html
View on StockTwits ↗$DXCM stock ticker ALRTF ($0.07) just partnered with $CVET to sell the GluCurve Pet CGM, the first and only Continuous Glucose Monitor for diabetic pets. ALRT is up and coming and will be launching an ultra low cost human CGM in 2024 that will put DXCM out of business. Great buying opportunity to get in on the ground floor of ALRT before they uplist to the NYSE American in Q1 https://finance.yahoo.com/news/alr-technologies-announces-co-branded-133300364.html
View on StockTwits ↗$ABT stock ticker ALRTF ($0.07) just partnered with $CVET to sell the GluCurve Pet CGM, the first and only Continuous Glucose Monitor for diabetic pets. This will hurt Libre 2 sales since veterinarians wont use it anymore. Great buying opportunity to get in on the ground floor of ALRT before they uplist to the NYSE American in Q1 https://finance.yahoo.com/news/alr-technologies-announces-co-branded-133300364.html
View on StockTwits ↗$ZTS stock ticker ALRTF ($0.07) just partnered with $CVET to sell the GluCurve Pet CGM, the first and only Continuous Glucose Monitor for diabetic pets. This will kill the AlphaTRAK 2 business. Great buying opportunity to get in on the ground floor of ALRT before they uplist to the NYSE American in Q1 https://finance.yahoo.com/news/alr-technologies-announces-co-branded-133300364.html
View on StockTwits ↗lawsuit scanner for $CVET https://www.lawow.org/gatto-frances-vs-ellinger-deborah-g-et-al-2022-09-14
View on StockTwits ↗lawsuit scanner for $CVET https://www.lawow.org/pascual-v-covetrus-inc-2021-06-03/
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.